Uso de los detonadores electrónicos Fametronic para evaluar la fragmentación de la roca en compañía minera Condestable S. A.

La realización de la presente tesis nace de una necesidad de conocer el comportamiento de los detonadores electrónicos tipo Fametronic en minería subterránea y ver el comportamiento del grado de fragmentación del material post voladura en tajeos de producción, zanjas y chimeneas slot en Compañía Minera Condestable S.A. El presente estudio analizará el comportamiento del factor de potencia con el uso de los detonadores electrónicos y pirotécnicos con la finalidad de controlar y reducir el grado de fragmentación de material post voladura. La tesis aplica el método analítico, es preexperimental donde se observa y analiza las diferentes variables de perforación y voladura considerando el uso de detonadores electrónicos y detonadores pirotécnicos en distintos frentes de operación. La realización de la presente tesis permitió el análisis de 24 disparos en voladuras en tajeos de producción, zanja y chimenea slot, con longitudes de taladro de 10 a 27 metros, con factores de carga de 30.74 a 144.67 kg/m y un factor de potencia promedio de 0.29 kg/t. Para el análisis de la granulometría, se comparó los detonadores electrónicos y detonadores pirotécnicos con 7 voladuras en tajeos de producción. Los resultados obtenidos, generados con detonadores pirotécnicos, fue de un P80 de 10.26” y un P80 de 6.80” para detonadores electrónicos. Esta reducción en la granulometría en 3.46” influye directamente en un menor consumo de energía en la etapa de conminución (chancado y molienda), así como en la optimización de los diferentes procesos unitarios de carguío y acarreo. XIV El menor grado de fragmentación generó una reducción de consumo de energía en 0.06 KWh/t, considerando un costo de energía de 0.30 $/ KWh, se genera un costo de fragmentación por tonelada de 0.018$/t. El menor costo de fragmentación por tonelada considera una importante reducción de costos mensuales en 2,700 $/mes y de 32,400$/año, considerando una producción mensual de 150,000 t/mes

Actualización catastral para aumentar los ingresos de tributos de bienes inmuebles (IBI)

El impuesto de bienes inmuebles brinda un importante aporte económico a la municipalidad al menos el 50% de la recaudación de tributos municipales, pero no todas las propiedades están registradas en el registro municipal, por lo que se realizan las actividades de actualización catastral de las diferentes zonas del municipio de villa el Carmen, principalmente en el caso de la zona 1 del casco urbano del municipio. Por medio de este trabajo se pretende aumentar el porcentaje en la parte monetaria de la municipalidad, para realizar un mejor proceso de planificación y proyección de planes a largo y corto plazo para el mejoramiento de las diferentes actividades ejecutadas dentro y fuera de la comuna. Este trabajo se ejecutó por medio de una serie de actividades para recopilar la información, encuestas, trabajos de campo y gabinete, que nos brindan las diferentes características físicas de las propiedades. Se logró la actualización de la base de datos de los lotes ubicados en la zona de trabajo. Seguir con la actualización catastral en la zona de trabajo así como a nivel del casco urbano

La administración del tiempo de ejecución de los proyectos de obra pública

Red Académica Internacional UADY, UAM-A, WPI, TAMU e invitados. Administración y Tecnología para Arquitectura, Diseño e Ingeniería.Una de las principales fuentes de conflicto entre constructores y clientes se deriva del incumplimiento en la fecha de entrega de la obra; cuando esto ocurre, clientes, constructores y usuarios sufren diferentes afectaciones. La buena administración del tiempo de ejecución de los proyectos es un indicador importante de la eficiencia, profesionalismo y capacidad del constructor, y también puede utilizarse para evaluar el éxito de un proyecto. En este trabajo se presenta el resultado de la evaluación del desempeño en el tiempo de ejecución de los proyectos de obra pública, así como la aplicación de un método desarrollado recientemente para dicho fin. Los resultados mostraron que la mitad de los proyectos estudiados no se terminaron en el tiempo contratado y que el método aplicado resultó más eficaz que el método tradicional basado en el costo

The Spatial and Temporal Construction of Confidence in the Visual Scene

Human subjects can report many items of a cluttered field a few hundred milliseconds after stimulus presentation. This memory decays rapidly and after a second only 3 or 4 items can be stored in working memory. Here we compared the dynamics of objective performance with a measure of subjective report and we observed that 1) Objective performance beyond explicit subjective reports (blindsight) was significantly more pronounced within a short temporal interval and within specific locations of the visual field which were robust across sessions 2) High confidence errors (false beliefs) were largely confined to a small spatial window neighboring the cue. The size of this window did not change in time 3) Subjective confidence showed a moderate but consistent decrease with time, independent of all other experimental factors. Our study allowed us to asses quantitatively the temporal and spatial access to an objective response and to subjective reports

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues